Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geny Piro

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
International Journal of Molecular Sciences|September 5, 2020
Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk StratificationVincenzo Nasca, Marta Chiaravalli, Geny Piro, et al.
Amino Acids|October 21, 2016
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostatCarmine Carbone, Elena Di Gennaro, Geny Piro, et al.
International Journal of Molecular Sciences|February 2, 2018
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and CancerCarmine Carbone, Geny Piro, Valeria Merz, et al.
International Journal of Molecular Sciences|October 28, 2018
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and ChemoresistancePriscilla Cascetta, Alessandro Cavaliere, Geny Piro, et al.
Journal of Cellular Physiology|June 11, 2011
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMTFrancesca Bruzzese, Alessandra Leone, Monia Rocco, et al.
Cancers|October 30, 2019
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old StoryGeny Piro, Carmine Carbone, Luisa Carbognin, et al.
Cancers|February 10, 2024
The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?Martina Panebianco, Chiara Ciccarese, Alessandro Strusi, et al.
European Journal of Neurology|July 4, 2023
Inflammatory profile in mitochondrial diseases: A cohort studyGuido Primiano, Domenico Plantone, Geny Piro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2020
The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-AnalysisChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.
Frontiers in Immunology|May 27, 2024
Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinomaBrigida Anna Maiorano, Giovanni Schinzari, Carmine Carbone, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Sciences|September 5, 2020
Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk StratificationVincenzo Nasca, Marta Chiaravalli, Geny Piro, et al.
Amino Acids|October 21, 2016
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostatCarmine Carbone, Elena Di Gennaro, Geny Piro, et al.
International Journal of Molecular Sciences|February 2, 2018
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and CancerCarmine Carbone, Geny Piro, Valeria Merz, et al.
International Journal of Molecular Sciences|October 28, 2018
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and ChemoresistancePriscilla Cascetta, Alessandro Cavaliere, Geny Piro, et al.
Journal of Cellular Physiology|June 11, 2011
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMTFrancesca Bruzzese, Alessandra Leone, Monia Rocco, et al.
Cancers|October 30, 2019
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old StoryGeny Piro, Carmine Carbone, Luisa Carbognin, et al.
Cancers|February 10, 2024
The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?Martina Panebianco, Chiara Ciccarese, Alessandro Strusi, et al.
European Journal of Neurology|July 4, 2023
Inflammatory profile in mitochondrial diseases: A cohort studyGuido Primiano, Domenico Plantone, Geny Piro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2020
The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-AnalysisChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.
Frontiers in Immunology|May 27, 2024
Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinomaBrigida Anna Maiorano, Giovanni Schinzari, Carmine Carbone, et al.
Pageof 6